We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A speech by Sarah Cardell, CEO of the Competition and Markets Authority (CMA), delivered at the CMA's 10 year anniversary event.
A. Menarini Farmaceutica Internazionale Srl is recalling a specific batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.
All data on CMA spending over £500 with an electronic purchasing card solution (ePCS) since March 2015.
Information about how the Competition and Markets Authority responded to the coronavirus (COVID-19) outbreak.
All data on external disclosures made to the CMA
Documents relating to workforce management information summary data for the Competition and Markets Authority.
Information about what to do if you receive a warning or advisory letter from the CMA.
This collection brings together all documents about our spend on non-consolidated performance related pay.
Tell the CMA about issues with a business, a market, or to provide information about a new or existing case.
Tell the CMA about competition and consumer issues.
Letters sent by the Competition and Markets Authority (CMA) to companies about their non-compliance with market investigation orders and undertakings.
This collection brings together all the Competition and Markets Authority's (CMA) board meeting minutes.
The Competition and Markets Authority (CMA) has published its response to the Ofcom’s consultation on prohibiting inflation-linked price rises.
This guidance explains how the CMA handles information and complaints we receive about businesses and business practices.
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
After extensive engagement, the CMA has published its Annual Plan for 2024 to 2025.
Following a provisional clearance in February, the CMA is now allowing the proposed deal between Arçelik and Whirlpool to go ahead.
The Competition and Markets Authority (CMA) has a statutory duty to comply with the Public Records Act 1958 (PRA).
Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML).
The CMA investigated alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.